1.
Maturitas
; 137: 57-62, 2020 Jul.
Article
in English
| MEDLINE | ID: covidwho-888706
ABSTRACT
COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents. For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic.
Subject(s)
Coronavirus Infections , Estrogen Replacement Therapy , Hormone Replacement Therapy , Menopause , Pandemics , Pneumonia, Viral , Thromboembolism , Anticoagulants/therapeutic use , Betacoronavirus , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/epidemiology , Female , Heparin, Low-Molecular-Weight/therapeutic use , Hormonal Contraception , Humans , Middle Aged , Pneumonia, Viral/complications , Pneumonia, Viral/epidemiology , Risk Factors , SARS-CoV-2 , Thromboembolism/etiology , Thromboembolism/prevention & control
2.
Maturitas
; 140: 81-82, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-704689
Subject(s)
Coronavirus Infections , Hormonal Contraception , Pandemics , Pneumonia, Viral , Betacoronavirus , COVID-19 , Estrogens , Female , Humans , Menopause , SARS-CoV-2
3.
Maturitas
; 138: 78-79, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-611712